Loading…
Develops therapies for hematologic diseases involving abnormal red blood cell production and iron metabolism.
Develops therapies for hematologic diseases involving abnormal red blood cell production and iron metabolism.
Develops drugs in-licensed rather than discovered in-house: bitopertin comes from Roche, which dropped it for a different disease. Money to run trials comes from investors until an approved product sells. Rare-disease drugs treat few patients, so they usually carry high prices.
Moat: none (IP / patents). Clinical-stage biotech targeting underserved rare hematologic diseases, with no approved products yet.
Headquarters: Watertown, Massachusetts, US · Founded: 2019 · Employees: 155
Size Disc Medicine (IRON) is a United States Health Care company (Biotechnology) with a market value of $3.50B, the 1432nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $78.91 on 6 Nov 2026.
Performance Over six months the shares gained 15.6%, against +3.9% for the median peer and -1.1% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Short interest Short interest is 19.4% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$355,000 | -$281,000 | -$156,000 | -$100,000 | -$300,000 |
| EBITDA | -$269M | -$236M | -$130M | -$91.0M | -$47.2M |
| Net income | -$246M | -$212M | -$109M | -$76.4M | -$46.8M |
| Free cash flow | -$198M | -$181M | -$94.4M | -$73.6M | -$42.4M |
| Capital expenditure | $46,000 | $933,000 | $505,000 | $89,000 | $151,000 |
| Total debt | $60.9M | $31.0M | $30.0M | $2.10M | $1.33M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Disc Medicine IRON | $3.50B | +16% | n/a | n/a | n/a | n/a |
| Alnylam Pharmaceuticals ALNY | $20.9B | -47% | +56% | 20% | 4.0× | 0.9% |
| Agios Pharmaceuticals AGIO | $1.76B | +6% | +141% | -467% | 11.9× | n/a |
| Rigel Pharmaceuticals RIGL | $741M | +52% | +3% | 31% | 2.5× | -1.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IRON | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +29.9% | +0.4% | 2nd highest of 21 |
| 6-month return | +15.6% | +3.9% | 9th highest of 21 |
| Distance from 52-week high | -20.7% | -25.0% | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Disc Medicine IRON | United States | $3.50B | +16% | n/a | n/a | n/a | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.62B | +21% | n/a | n/a | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.63B | -7% | +121% | -253% | 49.1× | n/a | n/a |
| Virbac VIRP.PA | France | $3.38B | +5% | +4% | 15% | 2.1× | 6.2% | +9.4% |
| Dyne Therapeutics DYN | United States | $3.37B | +3% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | 10.4× | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.37B | -15% | -11% | 17% | 5.6× | 16.7% | -1.8% |
| XtalPi 2228.HK | Hong Kong | $3.35B | -34% | +4% | -127% | 26.3× | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 4.8× | 3.2% | +12.5% |
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 3.9× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | 128.0× | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | 51.7× | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | 45.9× | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | 6,237.3× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 2.8× | -2.0% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | 5.5× | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.91B | +74% | +37% | 21% | 14.2× | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.85B | -9% | +20% | -3% | 6.1× | n/a | n/a |
| ADMA Biologics ADMA | United States | $2.85B | +56% | +8% | 42% | 5.7× | -0.8% | +64.6% |